Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant
Authors
Ruby Khoury, Division of Bone Marrow Transplant and Immune Deficiencies, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati, Cincinnati, OH. Electronic address: ruby.khoury@cchmc.org.
Michael S. Grimley, Division of Bone Marrow Transplant and Immune Deficiencies, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.
Adam S. Nelson, Division of Bone Marrow Transplant and Immune Deficiencies, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.
Tom Leemhuis, Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH.
Jose A. Cancelas, Department of Pediatrics, University of Cincinnati, Cincinnati, OH; Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Eleanor Cook, Division of Bone Marrow Transplant and Immune Deficiencies, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
YunZu Wang, Division of Bone Marrow Transplant and Immune Deficiencies, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.
Daria Heyenbruch, Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH.
Catherine M. Bollard, Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Hospital, the George Washington University, Washington, DC.
Michael D. Keller, Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Hospital, the George Washington University, Washington, DC.
Patrick J. Hanley, Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Hospital, the George Washington University, Washington, DC.
Carolyn Lutzko, Department of Pediatrics, University of Cincinnati, Cincinnati, OH; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Giang Pham, Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Stella M. Davies, Division of Bone Marrow Transplant and Immune Deficiencies, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.
Jeremy D. Rubinstein, Department of Pediatrics, University of Cincinnati, Cincinnati, OH; Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Document Type
Journal Article
Publication Date
4-19-2024
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
DOI
10.1016/j.ajt.2024.04.009
Abstract
Reactivation or primary infection with double stranded DNA viruses is common in recipients of solid organ transplants and is associated with significant morbidity and mortality. Treatment with conventional anti-viral medications is limited by toxicities, resistance, and lack of effective options for adenovirus and BKPyV. Virus-specific T-cells (VSTs) have been shown to be an effective treatment for infections with adenovirus, BKPyV, cytomegalovirus (CMV), and Epstein-Barr virus (EBV). Most of these studies have been conducted in stem cell recipients and no large studies have been published in the solid organ transplant population to date. In this study we report on the outcome of quadrivalent third party VST infusions in 98 recipients of solid organ transplants in the context of an open label phase 2 trial. The ninety-eight patients received a total of 181 infusions, with a median of 2 infusions per patient. The overall response rate was 45% for BKPyV, 65% for CMV, 68% for Adenovirus, and 61% for EBV. Twenty percent of patients with PTLD had a complete response and 40% a partial response. All the VST infusions were well tolerated. We conclude that VSTs are safe and effective in the treatment of viral infections in solid organ transplant recipients.
APA Citation
Khoury, Ruby; Grimley, Michael S.; Nelson, Adam S.; Leemhuis, Tom; Cancelas, Jose A.; Cook, Eleanor; Wang, YunZu; Heyenbruch, Daria; Bollard, Catherine M.; Keller, Michael D.; Hanley, Patrick J.; Lutzko, Carolyn; Pham, Giang; Davies, Stella M.; and Rubinstein, Jeremy D., "Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant" (2024). GW Authored Works. Paper 4700.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4700
